Welcome to #KCRS20!
October 22, 4:00-7:15 p.m. EDT
October 23, 8:00-11:00 a.m. EDT
KidneyCAN is proud to announce the 2nd annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP.
Building Global communication and collaboration
in the research community
Welcome to #KCRS20!
October 22, 4:00-7:00 p.m. EST
October 23, 8:00-11:00 a.m. EST
KidneyCAN is proud to announce the 2nd annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP.
Building Global communication and collaboration in the research community
Registration Open
Given the complications of COVID-19, #KCRS20 will be a virtual conference. Join us as we continue to fight for a cure!
Registration for this event is now open for Academic/Research attendees and Industry Representatives.
We are counting down!
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
#KCRS20 Agenda
Thursday, October 22nd
4:00-7:30 p.m. EDT
Registration
Event registration opens at 3:00 p.m. EST. Please use this opportunity to visit our sponsor pages!
Welcome
Welcome to #KCRS20! Introduction to our event, overview of topics and speakers, and information for navigating the virtual platform.
Keynote Presentation: "Can Studies of the VHL Gene Get Us to Curative Combination Therapies for Kidney Cancer?"
Dr. William G. Kaelin, Jr., Nobel Laureate
Dana Farber Cancer Institute
The Next Frontier: New Molecular Targets for Kidney Cancer
Moderated by Eric Jonasch, MD Anderson Cancer Center, and Naomi Haas, University of Pennsylvania.
“Therapeutic Targeting of Cystine Addiction of RCC”
Jen Tsan Chi, Duke University
“TBK1 Serves as a Novel Therapeutic Target in Kidney Cancers with VHL Loss”
Qing Zhang, University of Texas Southwestern
“Targeting IGF1R Signaling in MTAP-Deficient Kidney Cancer”
Ching-Hsien Chen, University of California Davis
“Studying BAP1 in Regulating Glucose Dependency in Renal Cancer: Mechanisms and Preclinical Translation”
Boyi Gan, MD Anderson Cancer Center
Break
Getting the Right Therapies to the Right Patients: Emerging Biomarkers for Kidney Cancer
Moderated by Sabina Signoretti, Dana Farber Cancer Institute, and Payal Kapur, University of Texas Southwestern.
“Characterizing and Targeting the Microenvironmental Barriers to Immunotherapeutic Response in RCC: Team Research”
Ari Hakimi & Tim Chan, Memorial Sloan Kettering Cancer Center
“Endogenous Retrovirus Expression, Chromatin Abnormalities, and Response to Immune Checkpoint Blockade in Clear Cell RCC”
Shridar Ganesan, Rutgers Cancer Institute
“Host Immune Signatures as Therapy Response Biomarkers in Metastatic Renal Cell”
Ziad Bakouny, Dana Farber Cancer Institute
“Development and Testing of Circulating-Free Methylation DNA as a Prognostic Biomarker for Recurrent Kidney Cancer”
Daniel De Carvalho, Princess Margaret Cancer Center
“Biomarkers of IO in RCC: What Is an Ideal Industry-Academic Relationship?”
[Presenter TBD]
Friday, October 23rd
7:00-11:00 a.m. EDT
Registration
Event registration opens at 7:00 a.m. EDT. Please use this opportunity to visit our sponsor pages!
Welcome
Welcome to Day Two of #KCRS20! Introduction to today’s topics and speakers, and information about the optional CME.
Best of 2020: Including Updates from ESMO
Moderated by Toni Choueiri, Dana Farber Cancer Institute, and Brian Rini, Vanderbilt University.
“Translational Science Updates from ESMO”
Tom Powles, Barts Cancer Centre
“Important Clinical Updates from ESMO”
Laurence Albiges, Institut Gustave Roussy
“The Ever-Changing Clinical Landscape of Kidney Cancer Therapies: Updates and Ongoing Trials”
Robert Motzer, Memorial Sloan Kettering Cancer Center
Break
Please use this opportunity to grab a drink or snack and visit our sponsor pages!
The Next Generation of Immune Therapies
Moderated by Hans Hammers, University of Texas Southwestern, and John Haanen, Netherlands Cancer Institute.
“Targeted Pro-Inflammatory Prodrugs for the Immunotherapy of Kidney Cancer”
Hans Hammers, University of Texas Southwestern
“Oncolytic Single-Cycle Replicating Immunotherapies for Kidney Cancer”
Michael Barry, Mayo Clinic
“Personalized T-Cell Immunotherapy for Renal Cell Carcinoma”
Shreeran Akilesh, University of Washington
“Lessons in Immunotherapy Failures”
Ira Mellman, Genentech, Cancer Immunology
Lunch
Please use this opportunity to eat lunch and visit our sponsor pages!
Optional CME Course: "The Emerging Role of Biomarkers in mRCC: Selecting Patients and Predicting Response to Treatment"
An optional CME course will be presented after the lunch break.
“Predicting Response to Immune Checkpoint Inhibition in Solid Tumors: Genomic Alterations and Immune Cell Infiltration in Advanced Clear Cell RCC”
Dr. Brian Shuch, University of California Los Angeles
“The Breadth of Biomarker Studies in mRCC: Surveillance and Drivers of Treatment Response”
Dr. David Braun, Dana Farber Cancer Institute
“Putting It All Together: Future Role of Biomarkers in Predicting mRCC Treatment Response”
Dr. Hans Hammers, University of Texas Southwestern
On-Demand Content
View pre-recorded sessions here!
The Next Frontier: New Molecular Targets for Kidney Cancer
“Profilin 1 as a Novel Target in Patients with RCC”
Partha Roy, University of Pittsburgh
“Functionally Characterizing the Enhancer Cistrome in Advanced Human Kidney Cancer”
[Presenter TBD]
Novel Models for Kidney Cancer Research
“Unlocking the Human Relevance of a New Genetic Papillary RCC Mouse Model”
Richard Link, Baylor College of Medicine
“Modeling Spatial Ecology in Clear Cell Renal Cell Carcinoma Model: A Novel Tool to Support Drug Sequencing Decisions”
Brandon Manley, H. Lee Moffitt Cancer Center
“Kidney Cancer (DFCI) Model”
Laura Stransky, Dana Farber Cancer Institute
“Kidney Cancer (UTSW) Model”
[Presenter TBD]
Evolving Imaging Methods for Improved Diagnosis and Response Prediction
“Noninvasive Diagnostic Assessment of Kidney Cancer Using Hyperpolarized 13C L-Tryptophan”
Lloyd Lumata, University of Texas at Dallas
“Immune Checkpoint Targeted Immuno-PET to Identify Therapy-Induced Adaptive Resistance: Research Partnerships”
Xiankai Sun, University of Texas Southwestern
“Quantitative CT Biomarkers to Predict Metastatic RCC Response to Antiangiogenic Therapy”
Andrew Smith, University of Alabama at Birmingham
Germline Genetics and Implications
“Biological Determinants of Kidney Cancer Health Disparities”
Khadijah Mitchell, Lafayette College
Variant Kidney Cancer Histologies: Characterization and Therapeutic Targeting
“Chromophobe RCC: New Concepts in Pathogenesis”
Elizabeth Henske, Brigham & Women’s Hospital
“Defining the Role of Beta-Catenin Activation in Wilms Tumor”
Keri Drake, University of Texas Southwestern
“Therapeutic Targeting of FLCN-Deficient Renal Cancers”
Othon Iliopoulos, Massachusetts General Hospital
“Molecular Characterization and Therapeutic Targeting of TFE3 Fusion Kidney Cancers”
Srinivas Viswanathan, Dana Farber Cancer Institute
#KCRS20 Partners
The second annual Kidney Cancer Research Summit is made possible through the generous contributions of our sponsors:
Ralph & Brenda Knapp
The Kidney Cancer Research Summit is also funded by KidneyCAN's grassroots supporters, a nationwide network of kidney cancer patients, caregivers, and family members who are committed to finding a cure.
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Program (CDMRP) or KCRP (Kidney Cancer Research Program).
KidneyCAN is a registered 501(c)(3) nonprofit grassroots organization dedicated to funding and finding a cure for kidney cancer.
Contact Us
KidneyCAN, 8327 Germantown Avenue, Philadelphia, PA 19118